Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Upcoming changes to drug precertification requirements for 2016

October 1, 2015

Effective January 1, 2016, new precertification requirements will apply to our commercial and Medicare Advantage HMO and PPO members for the seven medical benefit drugs listed below:
  • Adagen® (pegademase bovine)
  • Blincyto® (blinatumomab)
  • Cyramza® (ramucirumab)
  • KanumaTM (sebelipase alfa)*
  • Lemtrada® (alemtuzumab)
  • mepolizumab*
  • talimogene laherparepvec*
These changes will be reflected in an updated precertification requirement list, which will be posted to our website in December, prior to these changes going into effect. Look for more information about the availability of this new precertification requirement list in the December 2015 edition of Partners in Health UpdateSM.

*Pending approval from the U.S. Food and Drug Administration

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.